Novo Nordisk closes $1.35 billion Emisphere deal for oral semaglutide technology

Novo Nordisk completed its purchase of Emisphere Technologies on December 8, 2020, paying $1.35 billion for the company and the SNAC absorption-enhancer technology that makes oral semaglutide tablets possible ^[1]. SNAC is the piece of chemistry that allows semaglutide to be taken as a pill rather than an injection ^[1].

Novo Nordisk is a Danish pharmaceutical company based in Bagsværd that makes and sells Ozempic and Wegovy, both of which contain semaglutide ^[1]. The oral version of that molecule is sold as Rybelsus, and the same SNAC platform is expected to support a Wegovy pill described as coming in 2026 ^[1]. The acquisition put a delivery technology used across Novo Nordisk's semaglutide line under the company's own ownership rather than under a supplier's ^[1]. Novo Nordisk's product list also includes Saxenda, Victoza, Levemir and Tresiba, among others ^[1].

Novo Nordisk was formed in 1989 through the merger of two Danish insulin companies and is controlled by Novo Holdings A/S, which holds about 28.1 percent of its shares and 77.1 percent of its voting shares ^[1]. The company's market value passed the size of Denmark's national economy in 2023, making it the highest-valued company in Europe ^[1]. It employs 68,794 people and markets products in 168 countries ^[1]. Against that scale, $1.35 billion is a modest sum, and the company has not disclosed how it allocated that price among Emisphere's assets.

What else came with the purchase, beyond SNAC, has not been reported. Novo Nordisk has also not said whether other drugmakers will be able to license SNAC for their own products, or what terms would apply.

Why it matters for patients

Semaglutide is the active molecule in Ozempic, Wegovy and Rybelsus ^[1]. Two of those products are given by injection and one is a tablet, so the practical difference for a patient comes down to delivery technology rather than to the drug itself ^[1]. Because Novo Nordisk now owns SNAC outright, decisions about how oral semaglutide is developed, launched and priced sit with one company ^[1]. A rival manufacturer that wanted to sell an oral semaglutide product using the same absorption enhancer would need Novo Nordisk's agreement, and whether Novo Nordisk grants such agreements has not been reported.

People who would rather take a tablet than give themselves an injection are the group most directly affected by which oral forms exist. Whether the oral versions work as well as the injected ones, and how the two compare on cost or insurance coverage, is not addressed by the acquisition and has not been disclosed. Rybelsus was already on the market before the deal closed, so the transaction did not by itself add or remove a treatment option for patients ^[1].

What happens next

The Wegovy pill is described as a 2026 product ^[1]. No month, approval date, price or launch plan has been disclosed. Novo Nordisk has not reported whether SNAC will be used in other medicines in its pipeline, or whether the Emisphere purchase included manufacturing capacity for the technology ^[1].